Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19119290 | 0.87 | KMT2A (0.32) | KMT2ALMNARAB9AALDH1A1HTT | |
| SCHEMBL353971 | 0.87 | LMNA (0.38) | KMT2ALMNARAB9AALDH1A1HTT | |
| SCHEMBL354440 | 0.82 | ROCK2 (0.43) | KMT2ALMNAALDH1A1 | |
| SCHEMBL352427 | 0.78 | SMN1; SMN2 (0.35) | KMT2ALMNARAB9AALDH1A1HTT | |
| SCHEMBL353858 | 0.78 | HTT (0.42) | KMT2ALMNARAB9AALDH1A1HTT | |
| SCHEMBL353121 | 0.77 | ATG4B (0.36) | KMT2ALMNARAB9AALDH1A1HTT | |
| SCHEMBL352627 | 0.77 | ALDH1A1 (0.32) | KMT2ALMNARAB9AALDH1A1HTT | |
| SCHEMBL353752 | 0.76 | LMNA (0.39) | KMT2ALMNARAB9AALDH1A1HTT | |
| SCHEMBL354665 | 0.76 | ALDH1A1 (0.34) | KMT2ARAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL352911 | 0.76 | HSD11B1 (0.42) | KMT2ALMNARAB9AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | claimed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | claimed |
| US-8148380-B2 | Antibacterial amide and sulfonamide substituted heterocyclic urea compounds | CRESTONE, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | CRESTONE, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015941-A1 | Antibacterial Amide and Sulfonamide Substituted Heterocyclic Urea Compounds | NAAA, AADAC, RPSA | KMT2A 1210/4885LMNA 4293/4885RAB9A 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.